Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicroDose Technologies has entered into a global license agreement with Merck & Co., through an affiliate, for use of MicroDose's proprietary dry powder inhaler or DPI with Merck compounds.
Subscribe to our email newsletter
Under the terms of the agreement, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds.
MicroDose will receive an upfront payment and will be eligible for milestone payments totaling $32 million for successful development of the first product as well as royalties on product revenues. Additional products will also be eligible for milestones and royalties.